Literature DB >> 8440681

The platelet-activating factor acetylhydrolase from human erythrocytes. Purification and properties.

D M Stafforini1, E N Rollins, S M Prescott, T M McIntyre.   

Abstract

Platelet-activating factor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3- phosphocholine) is a biologically active phospholipid. Tissues, blood cells, and plasma contain PAF acetylhydrolases (calcium independent phospholipase A2 activities) that catalyze the hydrolysis of phospholipids containing short chain sn-2 acyl groups. They inactivate PAF and thereby determine PAF accumulation. We purified the PAF acetylhydrolase from human erythrocytes 15,600-fold. The enzyme has a molecular weight of 25,000, it behaves as a dimer during gel filtration, and it is a previously uncharacterized cytosolic esterase, as it has a unique amino-terminal sequence. The erythrocyte PAF acetylhydrolase requires the addition of sulfhydryl agents for maximal activity, is inhibited by 5,5'-dithiobis(2-nitrobenzoic acid), NaF, diisopropyl fluorophosphate, diethylpyrocarbonate, p-bromophenacylbromide, and a number of proteases. Antibodies against the purified protein precipitate all PAF hydrolase activity from erythrocyte lysates. The erythrocyte PAF acetylhydrolase is specific for short or oxidized sn-2 acyl residues. It exhibits surface dilution kinetics, suggesting that hydrolysis occurs at lipid interfaces. This suggests that this enzyme acts in vivo as a scavenger of oxidatively fragmented phospholipids that are toxic to the cell.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8440681

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  13 in total

1.  Circulating platelet-activating factor is primarily cleared by transport, not intravascular hydrolysis by lipoprotein-associated phospholipase A2/ PAF acetylhydrolase.

Authors:  Jinbo Liu; Rui Chen; Gopal K Marathe; Maria Febbraio; Weilin Zou; Thomas M McIntyre
Journal:  Circ Res       Date:  2010-12-23       Impact factor: 17.367

2.  Characterization of a platelet-activating factor acetylhydrolase secreted by the nematode parasite Nippostrongylus brasiliensis.

Authors:  M E Grigg; K Gounaris; M E Selkirk
Journal:  Biochem J       Date:  1996-07-15       Impact factor: 3.857

3.  Plasma levels of lipoprotein-associated phospholipase A(2) are increased in patients with β-thalassemia.

Authors:  Alexandros D Tselepis; George Hahalis; Constantinos C Tellis; Eleni C Papavasiliou; Panagiota T Mylona; Alexandra Kourakli; Dimitrios C Alexopoulos
Journal:  J Lipid Res       Date:  2010-07-12       Impact factor: 5.922

Review 4.  Metabolic processing of PAF.

Authors:  F Snyder
Journal:  Clin Rev Allergy       Date:  1994

5.  Density-associated changes in platelet-activating factor acetylhydrolase activity and membrane fluidity of human erythrocytes.

Authors:  H Yoshida; K Satoh; H Ishida; T Imaizumi; M Koyama; M Hiramoto; H Nakazawa; S Takamatsu
Journal:  Ann Hematol       Date:  1994-09       Impact factor: 3.673

6.  Phospholipase A2 from bovine seminal plasma is a platelet-activating factor acetylhydrolase.

Authors:  S Soubeyrand; C Lazure; P Manjunath
Journal:  Biochem J       Date:  1998-01-01       Impact factor: 3.857

7.  Anti-inflammatory HDL becomes pro-inflammatory during the acute phase response. Loss of protective effect of HDL against LDL oxidation in aortic wall cell cocultures.

Authors:  B J Van Lenten; S Y Hama; F C de Beer; D M Stafforini; T M McIntyre; S M Prescott; B N La Du; A M Fogelman; M Navab
Journal:  J Clin Invest       Date:  1995-12       Impact factor: 14.808

8.  Expression, purification and characterization of a human serine-dependent phospholipase A2 with high specificity for oxidized phospholipids and platelet activating factor.

Authors:  S Q Rice; C Southan; H F Boyd; J A Terrett; C H MacPhee; K Moores; I S Gloger; D G Tew
Journal:  Biochem J       Date:  1998-03-15       Impact factor: 3.857

9.  Platelet-activating factor acetylhydrolase deficiency. A missense mutation near the active site of an anti-inflammatory phospholipase.

Authors:  D M Stafforini; K Satoh; D L Atkinson; L W Tjoelker; C Eberhardt; H Yoshida; T Imaizumi; S Takamatsu; G A Zimmerman; T M McIntyre; P W Gray; S M Prescott
Journal:  J Clin Invest       Date:  1996-06-15       Impact factor: 14.808

10.  Aldose reductase-catalyzed reduction of aldehyde phospholipids.

Authors:  Sanjay Srivastava; Matthew Spite; John O Trent; Matthew B West; Yonis Ahmed; Aruni Bhatnagar
Journal:  J Biol Chem       Date:  2004-10-01       Impact factor: 5.157

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.